FDI in drugs and pharmaceuticals was $487 million during April-August 2012, according to the latest data of the Department of Industrial Policy and Promotion.
Not much is heard or read about Sun Pharma's media-shy owner.
The 30-share Sensex provisionally ended up 112 points at 28,555 and the 50-share Nifty closed 24 points higher at 8,561 after hitting a record high of 8,626.95.
USL is already contesting a Karnataka High Court order.
The 30-share Sensex ended 50 points lower at 28,112 and the 50-share Nifty declined 12 points to close at 8,531.
Top ten billionaires in India.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
Who is to take their place? Will a new generation of entrepreneurs start up with better business sense, or at least better luck? But the so-called unicorns are mostly copy-cat entrepreneurs whose cash flow is funded by overseas (including Chinese) money, notes T N Ninan.
Combined net profit estimated to grow 14.6% year-on-year, against a 5.7% decline in the Dec 2015 quarter
Sun Pharma stock has appreciated at 35% a year for 20 years
'The failures of private businessmen have set back the process of market-oriented reform, though that is the only way forward,' argues T N Ninan.
At present, there is no direct air connectivity between India and Myanmar.
The Sensex ended up 244 points at 28,504 on strong global cues.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
The S&P BSE Sensex has rallied about 28 per cent in 2014, after formation of a stable government at the Centre.
The National Pharmaceutical Pricing Authority will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources.
Sun Pharma's market capitalisation stood at Rs 100,050 crore on December 5, with its share price closing at Rs 417 a piece - lowest since March 2013.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
The year saw 30 QIP deals raising over $5 billion and 35 IPOs.
Top losers are Sun Pharma, Bajaj Auto, L&T, ITC, Hero Moto.
US will remain a growth driver, with launches & existing portfolios set to result in 15% growth for FY15.
Wockhardt MD Murtaza Khorakiwala said his firm had responded to the FDA's observations but declined to give details.
'15, 17 years back we were not even in existence in the US. Today nearly 1/3 of prescriptions written comes from India.' 'India is showing that in a very competitive environment -- like the US and Europe -- our industry is doing very well.'
Sahil Vachani fuels Analjit Singh's new business initiatives
The broader markets ended negatively with mid-caps and small-caps shedding 0.5 per cent on the BSE.
Samvat 2070 was a great year for top Indian conglomerates in the stock markets.
The top gainers on the Sensex were Cipla, Bharti Airtel, Maruti Suzuki, Hero Moto & Sesa Sterlite.
A glance back at some of the important ups and down Indian Inc faced in 2018.
The 30-share Sensex ended down 604 points at 28,845 and the 50-share Nifty ended down 181 points at 8,757. The Bank Nifty ended down 602 points at 19,146.
Inspections only in domestic authorities' presence, visiting US drug regulator told
Large and small businesses alike have delivered low-key performances.
The 30-share Sensex ended down 30.30 points at 28,161.72 and the 50-share Nifty dipped 7.95 points at 8,543.
Sensex, Nifty put up a good show in closing trade.
Nifty50 surged 87 points to end at 8,157, highest closing levels since Oct 29, 2015.
Mergers are not just about balance sheets or marketing synergies; they are also about those who make the synergies real.
With the July 1 deadline to apply for bank licence fast approaching, aspirants are scrambling to meet the Reserve Bank of India's (RBI) eligibility criteria to apply.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
The combined networth of India's 100 wealthiest is $381 billion (nearly Rs 25.5 lakh crore), a rise of 10 per cent from $ 345 billion in 2015
Few top honchos of India Inc did very well in 2014.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances